Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1439-1444

  Morine, Yuji ^a   Shimada, Mitsuo ^a   Utsunomiya, Tohru ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Mori, Hiroki ^a   Hanaoka, Jun ^a   Kanamoto, Mami ^a   Iwahashi, Shuichi ^a   Miyake, Hidenori ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hypoxia inducible factor 1 alpha; Immunohistochemistry; Multivariate analysis; Prognostic indicator

Indexed keywords

HYPOXIA INDUCIBLE FACTOR;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC CHOLANGIOCARCINOMA; LIVER RESECTION; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 83355163510     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11156     Document Type: Article

References (39)

1. Casavilla FA, Marsh JW, Iwatsuki S, Todo S, Lee RG, Madariaga JR, Pinna A, Dvorchik I, Fung JJ, Starzl TE: Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185:429-436. (Pubitemid 27475441)
2. Washburn WK, Lewis, WD, Jenkins RL: Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995; 130:270-276.
3. Roayaie S, Guarrera JV, Ye MQ, Thung SN, Emre S, Fishbein TM, Guy SR, Sheiner PA, Miller CM, Schwartz ME: Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Sug 1998; 187: 365-372. (Pubitemid 28467611)
4. Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H: Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreato Surg 1999; 6:108-116.
5. Kacznski J, Hanson G, Wallerstedt S: Incidence, etiologic aspects and clinicopathological features in intrahepatic cholangiocarcinoma - a study of 51 cases from a low endemicity area. Acta Oncol 1988; 37:77-83.
6. Chu KM, Lai EC, Al-Hadeedi S, Arcilla CE Jr, Lo CM, Liu CL, Fan ST, Wong J: Intrahepatic cholangiocarcinoma. World J Surg 1997; 21:301-306. (Pubitemid 27100493)
7. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Shimamura F, Shimizu Y, Miyazaki M: Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10:259-264. (Pubitemid 37407515)
8. Yamamoto M, Takasaki K, Yoshikawa T: Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreato Surg 1999; 6:117-121.
9. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-732.
10. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M: Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma correlation with poor prognosis with possible regulation. Pancreas 2008; 36:1-9.
11. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of Hypoxia-Inducible Factor-1α During Breast Carcinogenesis. Cancer 2003; 97:1573-1581.
12. Huang GW, Yang LY, Lu WQ: Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinomas: Impact on neovascularization and survival. World J Gastroenterol 2005; 11:1705-1708.
13. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, Price PM, Welch IM, West CM: Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007; 96:95-103. (Pubitemid 46094645)
14. Enatsu S, Iwasaki A, Shirakusa T, Hamasaki M, Nabeshima K, Iwasaki H, Kuroki M, Kuroki M: Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas on the lung. Eur J Cardiothorac Surg 2006; 29:891-895. (Pubitemid 43728579)
15. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y: Overexpression of hypoxia-inducible factor 1α and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 2006; 12:5112-5117. (Pubitemid 44453338)
16. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B: Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. European Urology 2006; 50:1272-1277. (Pubitemid 44692925)
17. Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, Koukourakis MI: Hypoxia inducible factors 1α and 2α are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 2006; 94:242-247. (Pubitemid 44289989)
18. Theodoropoulos VE, Lazaris ACh, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I: Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. European Urology 2004; 46:200-208. (Pubitemid 38902737)
19. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G: Austrian Breast and Colorectal Cancer Study Group: Overexpression of hypoxia-inducible factor la is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8:1831-1837. (Pubitemid 34633742)
20. Cleven AH, van Engeland M, Wouters BG, de Bruïne AP: Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol 2007; 29:229-240. (Pubitemid 46855703)
21. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, Yao M, Huang C: Expression of hypoxia-inducible factor-1a and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 2007; 30:1359-1367.
22. Liver Cancer Study Group of Japan: Classification of primary liver cancer. 1st English ed. Tokyo: Kanehara 1997.
23. Yamamoto M, Takasaki K, Yoshikawa T, Ueno K, Nakano M: Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma? J Surg Oncol 1998; 69:162-167. (Pubitemid 28549892)
24. El Rassi ZE, Partensky C, Scoazec JY, Henry L, Lombard-Bohas C, Maddern G: Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management. Eur J Surg Oncol 1999; 25:375-380. (Pubitemid 29364223)
25. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J: Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreato Surg 1999; 6:122-127.
26. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Cancer 2002; 89:1525-1531. (Pubitemid 35404319)
27. Sasaki A, Aramaki M, Kawano K, Morii Y, Nakashima K, Yoshida T, Kitano S: Intrahepatic peripheral cholangioma: mode of spread and choice of surgical treatment. Br J Cancer 1998; 85:1206-1209. (Pubitemid 28430419)
28. Shimada M, Yamashita Y, Aishima S, Shirabe K, Takenaka K, Sugimach: Hepatectomy for intrahepatic cholangiocarcinoma. Br J Cancer 2001; 88:1463-1466.
29. Chen WT, Huang CJ, Wu MT, Yang SF, Su YC, Chai CY: Hypoxia-inducible factor-1α is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal. Jpn J Clin Oncol 2005; 35:207-213.
30. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1a, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100:3767-3775. (Pubitemid 35303950)
31. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A: EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1- dependent mechanisms. Cancer Res 2006; 66:3197-3204.
32. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor la (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995-4004. (Pubitemid 32476461)
33. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12:122-127. (Pubitemid 43050086)
34. Yoo YG, Kong G, Lee MO: Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 2006; 25:1231-1241.
35. Kim SH, Kim KW, Jeong JW: Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression. Oncol Rep 2007; 17:793-797.
36. Kim SH, Jeong JW, Park JA: Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007; 17:647-651.
37. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 2010; 45:896-902.
38. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K: mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009; 69:7160-7164.
39. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM: Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28:3949-59.